Replies to post #10286 on Biotech Values

[poorgradstudent]

ok thanks

They could have used the forum to provide clinicians with an update as to the actual numbers they got from the interim 9902A look. Too bad... that's what these meetings are all about. They may have even gotten some more investigators interested in Provenge following the presentation of the numbers.

[DewDiligence]

>>When DNDN announced the progression miss and the interim 9902A survival data in January, they asked ASCO to pull the presentation. ASCO did, but apparently failed to inform their webmaster. Within one day or so of seeing it show up on the website, it was pulled from the website. Apparently, after January, it never was on the official agenda.<<

Why didn’t anyone correct the posts by ‘radiationcancerdoc’ and others from two weeks ago that touted the ASCO presentation?

If it was not widely known that the presentation had been pulled several months ago, some traders may have thought this was fresh dirt. If so, this could be an explanation, at least in part, for the immense weakness in the stock recently.